Sigilon Therapeutics, Inc. Profile Avatar - Palmy Investing

Sigilon Therapeutics, Inc.

Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with m…

Biotechnology
US, Cambridge [HQ]

Government Awards Analysis Beta

Obligations Over-Time

Awards
Obligations

Sigilon Therapeutics, Inc. has no obligation with a government/award agency.

Latest Obligations

Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
vs. Previous FY
Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0

Spending By Type

Awards
Obligations

Sigilon Therapeutics, Inc. can't present spending by time.

Get PRO Today

With PRO you will unlock all insights related to government awards of Sigilon Therapeutics, Inc..

End of SGTX's Analysis
CIK: 1821323 CUSIP: 82657L107 ISIN: US82657L1070 LEI: - UEI: -
Secondary Listings
SGTX has no secondary listings inside our databases.